Plné znění - 2/2008 Sb. m. s.

Xxxxxxxxxxxx zahraničních xxxx sděluje, xx xxx 16. xxxxxxxxx 2007 xxxx xxxxxxxxxx xxxxxxxxx UNESCO, depozitářem Xxxxxxxxxxx úmluvy xxxxx xxxxxxx xx sportu¹⁾, xxxxxxxx schválení nového xxxxx Přílohy I - Xxxxxxx xxxxxxxxxx xxxxx x xxxxx xxxxxxx.

Xxxxxxx X xxxxxxxxx x xxxxxxxx x xxxxxxx s článkem 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2008 a tímto xxxx xxxxxxxxx x xxxxxxxx i xxx Xxxxxx republiku. Dnem xxxxxx Přílohy X x xxxxxxxx xxxxxxxx xxxxxx Příloha X Xxxxxxxxxxx úmluvy proti xxxxxxx xx xxxxxx xx znění xxx xxx 2007, xxxxxxxxx xxx č. 59/2007 Xx. x. x.

Xxxxxxxx znění Xxxxxxx X a xxxx xxxxxxx xx xxxxxxx xxxxxx xx xxxxxxxxx xxxxxxxx.

X1. ANABOLICKÉ XXXXX

Xxxxxxxxxx xxxxx jsou xxxxxxxx.

1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (XXX):

x. Xxxxxxxx * XXX, zahrnující:

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3β,17β-xxxx); 1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx); xxxxxxxxx (19-xxxxxxxxxxxxxxxx); bolasteron; xxxxxxxx; xxxxxxx (androsta-1,4-dien-3,17-dion); xxxxxxx (17α-xxxxxxx-17β-xxxxxxxxxxxxxx-4-xxx[2,3-x]xxxxxxxx); dehydrochlormethyltestosteron (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxx-1,4-xxxx-3-xx); desoxymethyltestosteron (17α-metyl-5α-androst-2-en-17β-ol); xxxxxxxxxxx; xxxxxxxxxxxxx (19-xxx-17α-xxxxx-4-xx-17-xx); xxxxxxxxxxxxxx; formebolon; xxxxxxxxx (17β-xxxxxxx-17α-xxxxx-5α-xxxxxxxxxx[2,3-x]-xxxxxxx); xxxxxxxxx; 4-xxxxxxxxxxxxxxxxxx (4,17β-xxxxxxxxxxxxxxxx-4-xx-3-xx); xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; metandienon (17β-xxxxxxx-17α-xxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx (2α, 17α-xxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); xxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4,9-xxxx-3-xx); xxxxxx-1-xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxx-4-xx-3-xx); xxxxxxxxxxxxxxx (17β-hydroxy-17α-metylestra-4,9,11-trien-3-on); xxxxxxxxxxxxxxxxx; xxxxxxxxx; xxxxxxxxx; 19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx); norboleton; xxxxxxxxxxxxxx; xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx; prostanozol ([3,2-x]xxxxxxx-5α-xxxxxxxxxxxxxx-17β-xxxxxxxxxxxxxxxxx); xxxxxxxxx; xxxxxxxxxx; xxxxxxxxx; 1-xxxxxxxxxxx (17β-xxxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxx (18α-xxxx-xxxxxx-4,9,11-xxxxx-17β-xx-3-xx); trenbolon x xxxxx látky x podobnou xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx účinky.

x. Xxxxxxxxx ** AAS:

Xxxxxxxxxxxxx (xxxxxxx-5-xx-3β,17β-xxxx), xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx), xxxxxxxxxxxxxxxxxx, prasteron (xxxxxxxxxxxxxxxxxxxxx, XXXX), testosteron x následující metabolity x isomery:

5α-xxxxxxxxx-3α,17α-xxxx xxxxxxx-5-xx-3β,17α-xxxx

5α-xxxxxxxxx-3α,17β-xxxx 4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3β,17β-xxxx)

5α-xxxxxxxxx-3β,17α-xxxx 5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx)

5α-androstan-3β,17β-diol epi-dihydrotestosteron

androst-4-en-3α,17α-diol 3α-hydroxy-5αandrostan-17-on

xxxxxxx-4-xx-3α,17β-xxxx 3β-xxxxxxx-5αxxxxxxxxx-17-xx

androst-5-en-3β,17α-diol 19-norandrosteron

xxxxxxx-5-xx-3α,17α-xxxx 19-xxxxxxxxxxxxxxxxx

xxxxxxx-5-xx-3α,17β-xxxx

X xxxxxxxxx, xxx xxxx xxxx produkovat xxxxxxxxxx xxxxxxxxxx steroid xxxxxxxxx, xxxx xx mít xx xx, že Xxxxxx xxxxxxxx xxxx Xxxxxxxxx látku a xxxx hlášen xxxxxxxxx Xxxxxxxxx xxxxxxxxxxx xxxxx, xxxx xx koncentrace Xxxxxxxx xxxxx xxxx xxxxxx xxxxxxxxxx xxxx xxxxxxxxxxx x/xxxx xxxx xx xxxxxxxx xxxx xxxxxxxxx xxxxx xx Xxxxxx Xxxxxxxxx xxxxxxxx xxxxxxxxx od rozmezí xxxxxx, které se xxxxxxxx xxxxxxxxx u xxxx tak, že xxxxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxx. Xxxxxx se xxx xx to, xx Vzorek xxxxxxxx Xxxxxxxxx látku x xxxxxxx xxxxxxx, xxxxx Xxxxxxxxx xxxxxxx, xx xx xxxxxxxxxxx Xxxxxxxx xxxxx nebo jejích xxxxxxxxxx xxxx xxxxxxxxxx x/xxxx xxxxxxxxx poměr xx Vzorku Xxxxxxxxx xxxxxxxx xxxxxxxxxxxxx xxxx xxxxxxxxxxxx stavem.

Xxxx xx xxx xx xx, xx Vzorek Xxxxxxxxx xxxxxxxx Zakázanou xxxxx x xxxxxxxxx xxxxxxx Xxxxxxxxx xxxxxxxxxxx xxxxx ve xxxxx xxxxxxxxx x xxx xxxxxxxxx xxxxxxxxxxx, xxxxx xxx podle spolehlivé xxxxxxxxxx xxxxxx (xxxx. XXXX) xxxxxxxx, xx xx Xxxxxxxx látka xxxxxxxxxx xxxxxx. X xxxxxxx xxxxxxx není xxxxx xxxxxxxx další xxxxxxx.

Když xx xxxxxxx xxxxxxxx xxxxxxx xxxxxxxx xxxxxxxxxxx xx xxxxxxx xxxxxx, xxxxx xx xxxxxxxx xxxxxxxxx x xxxx x xxxxx spolehlivá analytická xxxxxx (xxxx. XXXX) xxxxxxxxxxx xxxxxxxx původ Xxxxxxxx xxxxx, ale xxxxxxxx xxxxxx xxxxxxx Xxxxxxxx látky, jako xxxx. xxxxxxxxx s xxxxxxxxxxx referenčními xxxxxxxxxxx xxxxxxx, xxxx xxxx xxxxxxxxx nahlásila poměr X/X xxxxx xxx xxxxx (4) xx xxxxx (1) x xxxxx spolehlivá analytická xxxxxx (xxxx. XXXX) xxxxxxxxxxx xxxxxxxx původ xxxxx, xxxxxxx xxxxxxxxx Xxxxxxxxxxxxx organizace xxxxx xxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxxxx testů xxxx xxxxxxxxxx následných testů.

Xx-xx xxxxxxxxxx xxxxxx xxxxx šetření, pak xxxxxxxx xxxx xxxxxxxxxx xxxxxx jako xxxxxxxxx x xx xxxx xxxxxxxxx. Pokud laboratoř xxxxxxx, xx xxxxxxx xxxxxxxxxx xxxxxxxxxx metody (xxxx. XXXX) xxxxxxxx xxxxx Zakázané xxxxx, xxxx xxxxx xxxxxxxx xxxxx šetření, x xxxx xx mít xx xx, že Xxxxxx xxxxxxxx Xxxxxxxxx xxxxx. Xxxxx nebyla xxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. IRMS) x xxxxxx x xxxxxxxxx xxxxxxxxx 3 xxxxxxxxx xxxxx, xxxx xxxxxxx longitudinální xxxxxx Xxxxxxxxx xxx, xx xxxx příslušnou Xxxxxxxxxxxxxx xxxxxxxxxx v xxxxxxxxxxxxx 3 xxxxxxxx třikrát xxxxxxxx xxx xxxxxxxxxxx xxxxxxxx. Xxxxxxxx, xxxxx xxxxxxxxxx tuto longitudinální xxxxxx, bude hlášen xxxx xxxxxxxxx. Xxxxx xxxxxxxxxxxxxx profil Xxxxxxxxx, xxxxxxxx následnými xxxxx, xxxx xxxxxxxxxxxx xxxxxxxx, xxxx xx xxx xxxxxxxxx za Xxxxxxxxx xxxxxxxxxxx xxxxx.

X xxxxxxxx xxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx může xxx x xxxx xxxxxx xxxxxxx boldenon endogenního xxxxxx ve xxxxxx xxxxxx xxxxxxxxxxxxx (xx/xx). Xxxxx laboratoř takový xxxxx nahlásila a xxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. XXXX) xxxxxxxxxxx exogenní původ Xxxxxxxx látky, xxxx xxx provedeno další xxxxxxx xxxxxxxxxx následného xxxxx (xxxxxxxxxx testů).

Xxxxx laboratoř nahlásila Xxxxxxxxx xxxxxxxxxxx xxxxx 19-xxxxxxxxxxxxxxx, bude xx xx považovat xx xxxxxxx x xxxxxxxxxxx xxxxx exogenního xxxxxx Xxxxxxxx xxxxx. X xxxxxxx xxxxxxx xxxx xxxxx provádět další xxxxxxx.

X xxxxxxx, xx Xxxxxxxxx xxxxxx xxxxxxxxxxxxx xxx xxxxxxx xxxxxxxxx, bude xx xxx za xx, xx Xxxxxx Xxxxxxxxx xxxxxxxx Xxxxxxxxx xxxxx.

2. Xxxxxxx xxxxxxxxxx xxxxx, xxxxxxxxxx:

Klenbuterol, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (SARM), xxxxxxx, xxxxxxx, zilpaterol, xxx xx x omezením xxxxx xx ně.

X2. XXXXXXX X PŘÍBUZNÉ XXXXX

Xxxxxxxxxxx xxxxx x xxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxxxx:

1. Erytropoetin (EPO);

2. Xxxxxxx hormon (xXX), xxxxxxxx podobné xxxxxxx xxxxxxx (např. XXX-1), xxxxxxxxxx růstové xxxxxxx (XXX);

3. Xxxxxxxxxxxxx (xxxx. XX, xXX), zakázané xxx x xxxx;

4. Xxxxxxxx;

5. Kortikotropiny

x další látky x podobnou chemickou xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx.

Xxxxx Xxxxxxxxx xxxxxx prokázat, xx xxxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxx či xxxxxxxxxxxx xxxxxx, xxxx xx xxx xx xx, xx Xxxxxx xxxxxxxx Xxxxxxxxx xxxxx (xxx je xxxxxxx xxxx) x xxxxxxxxx, xxx xxxxxxxxxxx Zakázané xxxxx nebo xxxxxx xxxxxxxxxx xx xxxxxxxxxx x/xxxx xxxxxxxxx xxxxxx xx Xxxxxx Xxxxxxxxx xxxxxxx xxxxxxxx hodnoty xxxxxxxx xxxxxxxx u xxxx xxx, že xxxxxxxxxxxx xxxxxxxx endogenní xxxxxxxx.

Xxxxx xxxxxxxxx xxxxxxxxx, xx xxxxx xxxxxxxxxx xxxxxxxxxx metody, xx Xxxxxxxx látka xx xxxxxxxxxx původu, xxxx xx mít xx xx, xx Xxxxxx xxxxxxxx Zakázanou xxxxx a bude xxxxxxx Xxxxxxxxx xxxxxxxxxxx xxxxx.

X3. XXXX-2 AGONISTÉ

Všichni xxxx-2 agonisté xxxxxx xxxxxx X- a X-xxxxxxx jsou xxxxxxxx.

Xxxxxxxx xxxx xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx x xxxxxxxxxx, pro xxxxx xx xxx xxxxxxxx xxxxx xxxxxxx xxxxxxxx xxxxxxxxxxxx výjimky.

X xxxx xxxx xxxxxxx xxxxxxxx xxxxx xxxxxxxxxxxx xxxxxxx, bude nález xxxxxxxxxxx (xxxxx xxxx xxxxxxxxxx) vyšší než 1000 xxxxxxxxx v 1 xxxxxxxxx moči xxxxxxxxx za Pozitivní xxxxxxxxxxx nález, xxxxx Xxxxxxxxx xxxxxxxxx, xx xxxxxxxxxx výsledek byl xxxxxxxx xxxxxxxxxxxxx xxxxxxxx xxxxxxxxxxx v inhalaci.

X4. XXXXXXXXXXX X XXXXXXXXXX HORMONŮ

Xxxxxxxxxxx xxxxxxx jsou xxxxxxxx:

1. Xxxxxxxxxx xxxxxxxx, xxxxxxxxxx:

2. Xxxxxxxxxx modulátory xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxxx:

3. Xxxxxxx antiestrogenní xxxxx xxxxxxxxxx:

4. Xxxxx modifikující funkce xxxxxxxxxx včetně xxxxxxxxxx xxxxxxxxxx, ale xx x xxxxxxxx xxxxx xx ně.

X5. DIURETIKA X XXXXXXX MASKOVACÍ XXXXX

Xxxxxxxxx látky xxxx zakázané. Zahrnují:

Xxxxxxxxx*, epitestosteron, probenecid, xxxxxxxxxx xxxx-xxxxxxxxx (např. xxxxxxxxxx, xxxxxxxxxx), plasmaexpandery (xxxx. xxxxxxx, dextran, xxxxxxxxxxxxxxxxx) a xxxxx xxxxx x xxxxxxxxx xxxxxxxxxxxx xxxxxx.

Xxxxxxxxx xxxxxxxx:

Acetazolamid, amilorid, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxx, xxxxxxxx, xxxxxxxx xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxx (xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx), triamteren x xxxxx látky x podobnou xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx (xxxxx xxxxxxxxxxxx, xxxxx xxxx xxxxxxxx).

* Xxxxxxxxxxxx xxxxxxx xxxx platná, xxxxx moč Xxxxxxxxx xxxxxxxx xxxxxxxxx xx xxxxxxx x xxxxxxxx xxxx xxxxxxxxxxx xxxxxxxx xxxx Xxxxxxxx xxxxx (xxxxx).

X1. XXXXXXXXX PŘENOSU XXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

X2. CHEMICKÁ X XXXXXXXXX XXXXXXXXXX

X3. XXXXXX DOPING

Neterapeutické xxxxxxx xxxxx, xxxx, xxxxxxxx elementů, xxxx xxxxxxxxxx xxxxxxx xxxx, xxxxx mají schopnost xxxxxx xxxxxxxxx xxxxx, xx xxxxxxxx.

X6. STIMULANCIA

Všechna xxxxxxxxxxx (včetně xxxx xxxxxx xxxxxxxxxx optických (X- a X-) xxxxxxx) xxxx zakázaná, x xxxxxxxx xxxxxxxx xxxxxxxxx x xxxxxxx xxxxxx xxxxxxxx xxxxx x xxxxxxxxxxx zahrnutých xx Xxxxxxxxxxxxxx xxxxxxxx xxx xxx 2008.

Xxxxxxxxxxx xxxxxxxx:

Xxxxxxxxx, xxxxxxxxx**, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxxx****, xxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, fenkamfamin, xxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, fenproporex, xxxxxxxxx, 4-xxxxxxxxxxxxxx (xxxxxxxx), xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxx, xxxxx***, xxxxxxxxxxx, xxxxxx, xxxxxxxxxxx, xxxxxxxxxx, levmetamfetamin, xxxxxxxxx, mefentermin, xxxxxxxxxxxx, xxxxxxxxxxxx (X-), xxxxxxxxxxxx****, xxxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxxxxxx, methylfenidát, xxxxxxxx, xxxxxxxxx, niketamid, xxxxxxxxxxx, xxxxxxxxxxxxxx, oktopamin, xxxxxxxxx, oxilofrin, xxxxxxxxxxxxxxxxxxxx, xxxxxxx, xxxxxxxxxxx, x-xxxxxxxxxxxxxxx, xxxxxxxxx, propylhexedrin, selegilin, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx x další xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

Xxxxxxxxxxxx xxxxxxxxx xxxxxxxx xxxx xxxxxxxx v xxxxx xxxxxx bude xxxxxxxxxx za xxxxxxxxxxx xxxxx xxxxx, pokud Xxxxxxxxx prokáže, že xxxx xxxxxxxxx dostupnost x běžných xxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxxxxxxxxx pravidel, xxxx xx x xxx menší xxxxxxxxxxxxxxx, xx xxxx úspěšně xxxxxxxx xxxx xxxxxxxxx xxxxx.

S7. XXXXXXXXX

Xxxxxxxxxxx narkotika xxxx zakázaná:

Xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx(xxxxxx), xxxxxxxx x xxxx xxxxxxxx, xxxxxxxxxxx, xxxxxxx, xxxxxx, xxxxxxxx, oxymorfon, xxxxxxxxxx, xxxxxxx.

X8. XXXXXXXXXXX

Xxxxxxxxxxx (např. xxxxx, xxxxxxxxx) xxxx xxxxxxxx.

S9. XXXXXXXXXXXXXXXXXXXX

Xxxxxxx xxxxxxxxxxxxxxxxxxxx xxxxxxxx xxxxxx, rektálně, xxxxxxxxxx nebo nitrosvalovou xxxxxxxx xxxx xxxxxxxx. Xxxxxx xxxxx xxxxxxxx xxxxxxxxxxxxx xxxxxxx.

Xxxx xxxxxxx injekční aplikace (xxxxxxxxxxxx, do xxxxx xxxxxx, do xxxxx xxxxxx, epidurální, xx xxxx) x inhalační xxxxxxxx xxxxxxxx zkrácenou xxxxxxxxxxxxx xxxxxxx x xxxxxxxx xxxx xxxxxxxxx.

Xxxxxxx xxxxxxxxx xxxxxxxx xx xxxxxx xxxxx (xxxxxx xxxxxxxxxxx/xxxxxxxxxx), xxxx, xxxxx, oční, xxxxxx xxxxx řitního otvoru, xxxxxxxx xxx a xxxxx xxxxxx zakázané x nevyžadují žádnou xxxxx xxxxxxxxxxxx xxxxxxx.

X1. XXXXXXX

Xxxxxxx (etanol) xx zakázaný xxxxx Xxx soutěži x xxxxxxxxxxxxx xxxxxxxx. Xxxxxxx xx xxxx xxxxxxxx xxxxxxxx xxxxxxxx a/nebo xxxxxxxx xxxx. Prahová xxxxxxx pro xxxxxxxx xxxxxxxxxxx xxxxxxxx (xxxxxxxxxxxxx xxxxxxx) xx pro xxxxxx xxxxxxxx xxxxxxx x xxxxxxxxx.

∙ Xxxxxxxxxxxx xxxxx (FIA) (0.10 x/x)

∙ Xxxxxx (WKF) (0.10 x/x)

∙ Xxxxxxx xxxxxx a xxxxxxxxxxxx (XXX) (0.20 x/x)

∙ Lukostřelba (XXXX, XXX) (0.10 g/l)

∙ Moderní xxxxxxx (XXXX) xxx xxx xxxxxxxxxx se střelbou (0.10 x/x)

∙ Xxxxxxxxxxx xxxxx (XXX) (0.10 g/l)

∙ Xxxxx xxxxxxxxxx (XXX) (0.30 x/x)

∙ Xxxxxxx (XXX) (0.10 g/l)

X2. XXXX-XXXXXXXXX

Xxxxx xxxx jinak xxxxxx, xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx Xxx xxxxxxx x xxxxxxxxxxxxx xxxxxxxx.

∙ Automobilový xxxxx (XXX)

∙ Xxxxxxxx (XXXX)

∙ Xxxx (XXXX)

∙ Xxxxx (XXX)

∙ Xxxxxxx (XXX)

∙ Xxxxxxxxxx (XXX)

∙ Xxxxxxxx (XXXX) - "xxxxx xxxx" - jen xxxxxxxxxxx

∙ Xxxxxxx (XXX)

∙ Xxxxxxx xxxxxx x parašutismus (XXX)

∙ Lukostřelba (XXXX, XXX) (xxxxxxxx xxxx Xxxx xxxxxx)

∙ Xxxxxxxx (XXX) - xxxxx xx xxxxxx x xxxxxxxxxxx xxxxxxxx-xxxxx x X-xxxxx, x snowboard X-xxxxx x "xxx xxx"

∙ Xxxxxxx xxxxxxx (XXXX) - xxx xxxxxxxxxx xx střelbou

∙ Xxxxxxxxxxx xxxxx (XXX)

∙ Xxxxxxxx x obdobné xxxxxx (XXXX, XXX "bowls")

∙ Střelba (ISSF, XXX) (zakázané xxxx Xxxx xxxxxx)

∙ Xxxxx xxxxxxxxxx (UIM)

∙ Xxxxx (FILA)

Xxxx-xxxxxxxxx zahrnují xxxxxxxxxxx xxxxx:

Xxxxxxxxxx, alprenolol, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxx, celiprolol, xxxxxxx, xxxxxxxxx, xxxxxxxxxx, labetalol, xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxx, oxprenolol, xxxxxxxx, xxxxxxxxxxx, sotalol, xxxxxxx, xxx xx s xxxxxxxx xxxxx xx xx

"Specifické látky"* xxxx vyjmenovány xxxx:

∙ Xxxxxxx Xxxx-2 xxxxxxxx v xxxxxxxx, xxxxx xxxxxxxxxxx (xxxxxxx xxxx xxxxxxxxxxx) xxx xxxxxxxx xxxxxx xxx 1000 xx/xx moči x xxxxxxxxxxxx (xxxxxxx xx skupině X 1.2 Xxxxxxx anabolické xxxxx);

∙ Inhibitory xxxx-xxxxxxxxx, probenecid;

∙ Xxxxx, xxxxxxxxxxx, xxxxxxxxxx, xxxxxxx, etamivan, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxxxxx, x-xxxxxxxxxxxxxx, xxxxxxxxxxxx, niketamid, norfenefrin, xxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxx a xxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxx v xxxxxx X6, pro která Xxxxxxxxx prokáže, že xxxxxxx podmínky xxxxxxx x oddíle X6;

∙ Xxxxxxxxxxx;

∙ Xxxxxxx Glukokortikosteroidy;

∙ Xxxxxxx;

∙ Xxxxxxx Xxxx-xxxxxxxxx.

*"X Xxxxxxx xxxxx xxx xxxxxxxxxxx xxxxxxxxxx látky, xxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxxxxxxxxx xxxxxxxx, xxxxxxx jsou všeobecně xxxxxxxx x xxxxxxx xxxxxxxxx přípravcích, nebo x nichž xx xxxxx xxxxxxxxxxxxxxx, že xxxxx úspěšně xxxxxxxx xxxx xxxxxxxxx xxxxxxx." Xxxxxxxx antidopingového xxxxxxxx xxxxxxxxxx takovéto xxxxx xxxx znamenat xxxxxxx xxxxxx za xxxxxxxxxxx, xx "...Xxxxxxxxx xxxx xxxxx prokázat, že Xxxxxxx xxxxxxxxxx látky xxxxxx xxxxxxxxx xx xxxxxxx xxxxxxxxxxx xxxxxx...".

Xxxxxx xxxxxxx x. 2/2008 Xx. m. x. xxxxx účinnosti xxxx 31.1.2008.

Xxxxxx xxxxxxx č. 2/2008 Sb. m. x. byl xxxxxx xxxxxxx xxxxxxxxx č. 8/2009 Sb. m. s. x účinností od 7.2.2009.

Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx právních xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx xx xxxx xxxxxx derogační xxxxx shora xxxxxxxxx xxxxxxxx xxxxxxxx.